Satellos Bioscience (MSLE) Capital Expenditures (2026)
Satellos Bioscience's (MSLE) quarterly Capital Expenditures came in at -$4000.0 in Q1 2026.
Satellos Bioscience (MSLE) Capital Expenditures (2026) Analysis & Trends
Satellos Bioscience (MSLE) has 1 years of Capital Expenditures data on file, last reported at -$4000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.41 Bn | 466.62 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 122.15 Bn | 114.90 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 69.94 Bn | 61.18 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.43 Bn | 62.43 Bn | - | - |
| 8 | Argenx Se | 55.85 Bn | 50.67 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Satellos Bioscience | 177.16 Mn | 177.16 Mn | - | -4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,000.00 |
| Mar 31, 2026 | -4,000.00 |